Dragonfly Research LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$463,341	150
2024	Research	$768,172	174
2023	Research	$449,282	162
2022	Research	$520,428	78
2021	Research	$614,407	141
2020	Research	$697,803	116
2019	Research	$991,026	61

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $2,473,862 213 payments
Biogen, Inc. $749,879 18 payments
Novartis Pharmaceuticals Corporation $538,051 14 payments
Genzyme Corporation $377,692 46 payments
Roche Products Limited $199,480 333 payments
EMD Serono, Inc. $121,959 245 payments
F. Hoffmann-La Roche AG $43,536 13 payments

Studies the money was for Research payments · program years 2019–2025

Ensemble $730,530 85 payments
A Phase III Study to Evaluate the Efficacy and Safety of Fenebrutinib in Adults With Progressive Ms $649,129 25 payments
Ocrelizumab RMS High Dose Study $636,446 32 payments
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $314,358 13 payments
A Single-Arm, Prospective, Multi-Center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-Cd20 Monoclonal Antibody (Acd20 Mab) Therapy (Olikos) $288,130 2 payments
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) $282,724 3 payments
Primary Ms $257,866 54 payments
A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment $216,462 1 payment
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration $214,800 2 payments
Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment $199,480 333 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.